Gujarat Kidney and Super Speciality Ltd
Gujarat Kidney and Super Speciality Ltd (GKSL) last reported results for the quarter ended Jun 2026, with sales of ₹34.29 crore and net profit of ₹5.32 crore. The stock last traded at ₹189, a market capitalisation of ₹1,491 crore, on a P/E of 94.2. Over the past 52 weeks the stock has ranged between ₹98.2 and ₹210. Figures are as of 6 Oct 2026 and are not real time.
Gujarat Kidney and Super Speciality Ltd share price and key metrics
- Current price
- ₹189
- Market cap
- ₹1,491 cr
- Stock P/E
- 94.2
- Book value
- ₹32
- ROE
- 11.1%
- ROCE
- 14.5%
- Dividend yield
- 0.00%
- 52w high / low
- 210/98.2
Metrics as of 6 Oct 2026. Not real time.
Track Gujarat Kidney and Super Speciality Ltd
Cruxal reads every Gujarat Kidney and Super Speciality Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Gujarat Kidney and Super Speciality Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 119%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 1058%
- TTM
- 37%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 16%
- Last Year
- 11%
Gujarat Kidney and Super Speciality Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹34.29 cr, up 124.7% from ₹15.26 cr a year earlier. Net profit was ₹5.32 cr, down 1.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9.41 | 11.79 | 9.78 | 15.26 | 12.93 | 23.25 | 30.58 | 34.29 |
| Expenses | 4.55 | 7.19 | 7.17 | 6.64 | 7.81 | 16.35 | 24.28 | 25.92 |
| Operating profit | 4.86 | 4.6 | 2.61 | 8.62 | 5.12 | 6.9 | 6.3 | 8.37 |
| OPM % | 51.65% | 39.02% | 26.69% | 56.49% | 39.60% | 29.68% | 20.60% | 24.41% |
| Other income | 0.04 | 0.05 | 0.05 | 0.01 | 0.09 | 0.06 | 0.71 | 0.69 |
| Interest | 0.16 | 0.17 | 0.16 | 0.18 | 0.28 | 0.6 | 0.82 | 0.66 |
| Depreciation | 0.74 | 0.88 | 0.9 | 0.96 | 0.9 | 1.33 | 1.51 | 1.44 |
| Profit before tax | 4 | 3.6 | 1.6 | 7.49 | 4.03 | 5.03 | 4.68 | 6.96 |
| Tax % | 26.25% | 29.72% | 16.88% | 27.77% | 28.54% | 26.44% | -2.99% | 23.56% |
| Net profit | 2.96 | 2.53 | 1.34 | 5.4 | 2.88 | 3.7 | 4.82 | 5.32 |
| EPS (₹) | 18.39 | 15.53 | 0.23 | 0.85 | 0.47 | 0.37 | 0.64 | 0.66 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gujarat Kidney and Super Speciality Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 0 | 5 | 40 | 82 | 101 |
| Operating profit | -0 | 2 | 17 | 27 | 27 |
| OPM % | — | 41% | 41% | 33% | 26% |
| Net profit | -0 | 2 | 10 | 17 | 17 |
| EPS (₹) | -0.50 | 85.50 | 1.66 | 1.97 | 2.14 |
TTM is the trailing twelve months to the most recent quarter.
Gujarat Kidney and Super Speciality Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 0.20 | 0.20 | 11 | 16 |
| Reserves | 0 | 11 | 15 | 237 |
| Borrowings | 0 | 6 | 8 | 29 |
| Other liabilities | 4 | 4 | 21 | 16 |
| Total liabilities | 4 | 21 | 55 | 298 |
| Fixed assets | 0 | 14 | 31 | 129 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 12 |
| Other assets | 4 | 7 | 24 | 157 |
| Total assets | 4 | 21 | 55 | 298 |
As reported by the company. Total assets equal total liabilities by construction.
Gujarat Kidney and Super Speciality Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 0 | 1 | 14 | -4 |
| Cash from investing | 0 | 0 | -18 | -214 |
| Cash from financing | 0 | -0 | 6 | 228 |
| Net cash flow | 0 | 1 | 2 | 11 |
| Free cash flow | 0 | 2 | -5 | -98 |
| CFO / operating profit | 0% | 70% | 99% | 21% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Gujarat Kidney and Super Speciality Ltd operating ratios
| Per year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 19% | 52% | 14% |
| Debtor days | 321 | 138 | 172 |
| Cash conversion cycle | 321 | 138 | 172 |
| Working capital days | 100 | -24 | 91 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Gujarat Kidney and Super Speciality Ltd shareholding pattern
Promoters held 71.45% at Jun 2026, broadly unchanged since Dec 2025. FIIs 4.89% and DIIs 0.56%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 71.45% | 71.45% | 71.45% |
| FIIs | 10.47% | 4.89% | 4.89% |
| DIIs | 1.67% | 0.56% | 0.56% |
| Public | 16.40% | 23.10% | 23.10% |
| No. of shareholders | 27,783 | 18,301 | 18,301 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Gujarat Kidney and Super Speciality Ltd corporate filings
- Certificate under Reg 74 (5) of SEBI (DP) RegulationsCompany Updatelow impact
- Gujarat Kidney and Super Speciality Limited passes all resolutions at AGM, including appointment of directors and approval of financialsAGM/EGMlow impact
Cruxal's analysis: Gujarat Kidney and Super Speciality Limited conducted its 7th AGM on 28th September 2026…
Read the full analysis - Gujarat Kidney And Superspeciality Limited Concludes 7th AGM; Shareholders Approve Key Governance and Financial ResolutionsAGM/EGMlow impact
Cruxal's analysis: Gujarat Kidney And Superspeciality Limited has successfully concluded its 7th Annual…
Read the full analysis - Intimation of Trading window closureInsider Trading / SASTlow impact
- Gujarat Kidney and Super Speciality Ltd issues corrigendum to Annual Report 2026Otherslow impact
Cruxal's analysis: The company has issued a corrigendum regarding its Annual Report for the financial year…
Read the full analysis - Gujarat Kidney and Super Speciality Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: The company has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Gujarat Kidney and Superspeciality Limited Announces 7th AGM with Proposals for Remuneration Revision and Borrowing LimitsAGM/EGMlow impact
Cruxal's analysis: Gujarat Kidney and Superspeciality Limited has issued a notice for its 7th Annual General…
Read the full analysis - Gujarat Kidney and Super Speciality Ltd files revised Annual ReportOtherslow impact
Cruxal's analysis: The company has submitted a revised version of its Annual Report. This is a routine…
Read the full analysis - Gujarat Kidney and Super Speciality Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: The company has filed its Annual Report for the financial year 2025-26 as per regulatory…
Read the full analysis - Gujarat Kidney and Super Speciality Ltd issues pre-advertisement notice for Annual General MeetingCompany Updatelow impact
Cruxal's analysis: The company has issued a routine pre-advertisement notice regarding its upcoming Annual…
Read the full analysis - Gujarat Kidney and Superspeciality Limited announces participation in GIA Healthcare Day investor meetCompany Updatelow impact
Cruxal's analysis: Gujarat Kidney and Superspeciality Limited has filed an intimation regarding its…
Read the full analysis - Gujarat Kidney and Super Speciality Limited Announces Board Appointment and IPO Proceeds Utilization UpdateOtherslow impact
Cruxal's analysis: Gujarat Kidney and Super Speciality Limited has appointed Dr. Disha Bharpoda as an…
Read the full analysis - Gujarat Kidney and Super Speciality Limited shareholders approve variation in IPO proceeds utilizationAGM/EGMlow impact
Cruxal's analysis: Gujarat Kidney and Super Speciality Limited has received shareholder approval via postal…
Read the full analysis - Gujarat Kidney and Super Speciality Ltd files Monitoring Agency Report for June 2026Company Updatelow impact
Cruxal's analysis: The company has submitted its Monitoring Agency Report for the period ending June 2026 in…
Read the full analysis - Gujarat Kidney and Super Speciality Ltd files Statement of Deviation or Variation for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: The company has submitted its Statement of Deviation or Variation regarding the…
Read the full analysis - Gujarat Kidney And Superspeciality Limited Appoints Mr. Paresh Dhoti as Additional Non-Executive Independent DirectorCompany Updatelow impact
Cruxal's analysis: Gujarat Kidney And Superspeciality Limited has announced the appointment of Mr. Paresh…
Read the full analysis - Gujarat Kidney and Superspeciality Limited Reports Q1 FY2027 Financial Results and Appoints Independent DirectorBoard Meetingmedium impact
Cruxal's analysis: Gujarat Kidney and Superspeciality Limited reported standalone revenue of 9.24 crore for…
Read the full analysis - Gujarat Kidney And Superspeciality Limited schedules Board Meeting for June 2026 quarterly resultsBoard Meetinglow impact
Cruxal's analysis: Gujarat Kidney And Superspeciality Limited has formally notified the stock exchanges that…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.